Prescription drug · NDA
Exelon (rivastigmine) NDC 66758-143
Rivastigmine 9.5 mg/24h · Patch, Extended release · Transdermal · Sandoz Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 66758-143-31 | 66758014331 | 30 PATCH in 1 CARTON (66758-143-31) / 24 h in 1 PATCH (66758-143-58)Marketed from Oct 3, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Exelon
- Generic name (nonproprietary)
- rivastigmine
- Active ingredients
- Rivastigmine — 9.5 mg/24h
- Dosage form
- Patch, Extended release
- Route
- Transdermal
- Labeler
- Sandoz Inc
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 022083
- Marketing start
- Listing expires
- Other FDA classes
- Cholinesterase Inhibitors (Mechanism)
- Identifiers
- Product ID 66758-143_b6ed6d15-116d-4596-92ce-3414574d7ba0SPL ID b6ed6d15-116d-4596-92ce-3414574d7ba0SPL set ID b6ed6d15-116d-4596-92ce-3414574d7ba0RxCUI 725021, 725023, 725105, 751302, 1308569, 1308571UNII PKI06M3IW0
- Pharmacologic class
- Cholinesterase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Transdermal products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N466758014331followed by a unit qualifier and the quantityPackage 66758-0143-31. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: • Mild, moderate, and severe dementia of the Alzheimer’s type (AD). ( 1.1 ) • Mild-to-moderate dementia associated with Parkinson’s disease (PD). ( 1.2 ) 1.1 Alzheimer’s Disease EXELON PATCH is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. 1.2 Parkinson’s Disease Dementia EXELON PATCH is indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PDD).
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 022083
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Exelonrivastigmine | Rivastigmine 4.6 mg/24h | Patch, Extended releaseTransdermal | Novartis Pharmaceuticals Corporation | 0078-0501 |
| Exelonrivastigmine | Rivastigmine 9.5 mg/24h | Patch, Extended releaseTransdermal | Novartis Pharmaceuticals Corporation | 0078-0502 |
| Exelonrivastigmine | Rivastigmine 13.3 mg/24h | Patch, Extended releaseTransdermal | Novartis Pharmaceuticals Corporation | 0078-0503 |
| Exelonrivastigmine | Rivastigmine 13.3 mg/24h | Patch, Extended releaseTransdermal | Sandoz Inc | 66758-144 |
| Exelonrivastigmine | Rivastigmine 4.6 mg/24h | Patch, Extended releaseTransdermal | Sandoz Inc | 66758-142 |
| Rivastigmine | Rivastigmine 4.6 mg/24h | Patch, Extended releaseTransdermal | Sandoz Inc | 0781-7304 |
| Rivastigmine | Rivastigmine 9.5 mg/24h | Patch, Extended releaseTransdermal | Sandoz Inc | 0781-7309 |
| Rivastigmine | Rivastigmine 13.3 mg/24h | Patch, Extended releaseTransdermal | Sandoz Inc | 0781-7313 |